It was reported here in November 2017 that two “anti-Ang2” drugs are being studied as potential combination therapies with established anti-VEGF treatments. RG7716 is being tested in combination with Lucentis (Genentech), and nesvacumab (REGN910) is being tested in combination with Eylea (Regeneron). Genentech has now reported that its Phase 2 BOULEVARD trials with RG7716 have [Read More]
News
Low Vision Lighting Technology is Improving
by Dan Roberts Advancements in lighting technology for the visually impaired have made big strides during the past 12 years. Before 2005, companies were touting their new full spectrum (“daylight”) lamps as “healthy for aging eyes”. Patients, and even their doctors, were led to believe that the sun at high noon is the best and [Read More]
First AMD Patient Receives Sub-Retinal Implant
(Updated 4/17/18) Pixium Vision has announced its first successful human implantation of a wireless sub-retinal implant in a patient with atrophic dry age-related macular degeneration (AMD). So far, three patients have been implanted with the device, and results are promising. As reported here in October 2017, the implant, called PRIMA, acts like a tiny solar [Read More]
Apellis Entering Phase 3 Trials for Dry Macular Degeneration
Apellis Pharmaceuticals has announced that it has finalized the trial design for its planned Phase 3 program evaluating APL-2 for the treatment of patients with geographic atrophy (GA), aka dry macular degeneration. The Phase 3 program, planned to begin in the second half of 2018, will consist of two identical studies to assess the efficacy [Read More]
FDA Approves First Gene Therapy for Inherited Retinal Dystrophy
The U.S. Food and Drug Administration (FDA) has approved Luxturna (voretigene neparvovec-rzyl), a new gene therapy developed by Spark Therapeutics, to treat an inherited form of vision loss that can result in blindness. The most prevalent inherited retinal dystrophies are retinitis pigmentosa (RP), Leber congenital amaurosis (LCA) and Stargardt disease (SD), all of which have [Read More]